NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million
Nanobiotix s ADSs began trading on the Nasdaq Global Select Market on December 11, 2020.
Announced full exercise of underwriters option to purchase additional American Depositary Shares (ADSs), with closing expected to take place on December 18, 2020. Will add approximately $14.8 million in additional gross proceeds for total of $113.3 million in gross proceeds from the offering.
Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205 the
Company ), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the initial closing of its previously announced initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,300,000 new ordinary shares (the